Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Down 62.7% in February

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 15,500 shares, a decline of 62.7% from the January 31st total of 41,500 shares. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily volume of 143,200 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Price Performance

Shares of NASDAQ:SNOA traded up $0.07 on Friday, reaching $2.27. 25,438 shares of the company traded hands, compared to its average volume of 43,747. The stock has a market capitalization of $3.67 million, a PE ratio of -0.56 and a beta of 1.43. The company’s 50 day moving average is $2.61 and its 200-day moving average is $2.62. Sonoma Pharmaceuticals has a fifty-two week low of $2.15 and a fifty-two week high of $9.37.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its earnings results on Wednesday, February 5th. The company reported ($0.59) earnings per share for the quarter. Sonoma Pharmaceuticals had a negative net margin of 26.82% and a negative return on equity of 68.98%. As a group, analysts expect that Sonoma Pharmaceuticals will post -0.67 EPS for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.